Skip to main content
Atrás
Watch Compare

Cyclerion Therapeutics, Inc.

Calidad de datos: 100%
CYCN
NASDAQ Manufacturing Chemicals
$3.10
▲ $0.21 (7.27%)
Cap. Mercado: 13.42 M
6 months return
—
Momentum
Neutral
5Y revenue growth
-14.83%

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -14.83% annually over 5 years
Negative free cash flow of -3.31 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 18.53%

Price History

Crecimiento

Revenue Growth (5Y)
-14.83%
Below sector avg (1.82%)
Revenue (1Y)3.70%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-38.97%
Above sector avg (-54.47%)
ROIC-43.39%
Net Margin-170.11%
Op. Margin-239.78%

Seguridad

Debt / Equity
N/A
Current Ratio5.78
Interest CoverageN/A

Valoración

PE (TTM)
-3.80
Below sector avg (-1.49)
P/B Ratio1.41
EV/EBITDAN/A
Dividend YieldN/A

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1605 pares)
Métrica Acción Mediana del Sector
P/E -3.8 -1.5
P/B 1.4 1.6
ROE % -39.0 -54.5
Net Margin % -170.1 -41.5
Rev Growth 5Y % -14.8 1.8
D/E — 0.3

Precio Objetivo de Analistas

1 analista

Consenso de analistas: objetivo medio vs precio actual y calificación.

Hold
Actual
$3.10
+158.1%
Objetivo
$8.00
$8.00
$8.00
$8.00
Pronóstico
EPS Futuro -$0.99
Ingresos Est. 0.0

Estimaciones de Ganancias

Pronósticos de EPS e ingresos por período. Anual = años fiscales; trimestral = próximos trimestres.

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.99
-$0.99 – -$0.99
0.0 1
FY2026 -$1.20
-$1.20 – -$1.20
0.0 1

Sorpresas de Ganancias

Últimos 2 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.38 -$0.19 +50.0%
Q32025 — -$0.30 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 3.70% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14.83% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.07 M Net Income (TTM) -3.53 M
ROE -38.97% ROA -35.66%
Gross Margin N/A Operating Margin -239.78%
Net Margin -170.11% Free Cash Flow (TTM) -3.31 M
ROIC -43.39% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.78
Interest Coverage N/A Asset Turnover 0.21
Working Capital 4.19 M Tangible Book Value 9.54 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.80 Forward P/E N/A
P/B Ratio 1.41 P/S Ratio 6.47
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24.69%
Market Cap 13.42 M Enterprise Value 8.86 M
Per Share
EPS (Diluted TTM) -1.11 Revenue / Share 0.48
FCF / Share -0.77 OCF / Share -0.77
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 93.93%
SBC-Adj. FCF -3.80 M Growth Momentum 18.53

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.07 M 2.00 M 0.0 1.63 M 3.94 M
Net Income -3.53 M -3.06 M -5.26 M 44.10 M -51.65 M
EPS (Diluted) -1.11 -1.21 -2.25 -1.01 —
Gross Profit — — — — —
Operating Income -4.97 M -3.63 M -12.95 M -44.37 M -55.20 M
EBITDA — — — — —
R&D Expenses 959,000.0 286,000.0 1.52 M 31.49 M 37.64 M
SG&A Expenses — — — — —
D&A — — 0.0 65,000.0 472,000.0
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.99 M 9.58 M 13.37 M 18.08 M 59.33 M
Total Liabilities — — — — —
Shareholders' Equity 9.09 M 8.85 M 11.29 M 10.45 M 48.25 M
Total Debt — — — 3.50 M 3.50 M
Cash & Equivalents 3.24 M 3.23 M 7.57 M 13.38 M 53.96 M
Current Assets 4.64 M 4.23 M 8.02 M 14.82 M 55.46 M
Current Liabilities 900,000.0 725,000.0 2.09 M 7.63 M 11.09 M